Chin MP, et al. - In order to characterize bardoxolone methyl-induced changes in kidney function in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) stage 4, post-hoc analyses were performed from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. In this patient population, researchers found that bardoxolone methyl not only preserved kidney function but also may delay the onset of end-stage renal disease (ESRD).